Showing 8011-8020 of 8647 results for "".
- WHO Declares COVID-19 Outbreak a Pandemic; Eye Care Meetings Cancelledhttps://modernod.com/news/who-declares-covid-19-outbreak-a-pandemic/2477374/The World Health Organization on Wednesday said the COVID-19 outbreak can now “be characterized as a pandemic.” The declaration by Director-General Tedros Adhanom Ghebreyesus was made after he noted that “in the past 2 weeks the number of cases outside China has increased thirteen-fold and the nu
- Reichert Technologies Signs Exclusive Deal for CATS Reusable Tonometer Prismshttps://modernod.com/news/reichert-technologies-signs-exclusive-deal-for-cats-reusable-tonometer-prisms/2477372/Reichert Technologies has announced its exclusive partnership with CATS Tonometer to distribute the CATS Reusable Tonometer Prism in the United States. The patented CATS Tonometer Prism is superior in IOP accuracy to traditional Goldmann prism, according to a company news release. “For dec
- Jim Mazzo Receives the Ellis Island Medal of Honorhttps://modernod.com/news/jim-mazzo-receives-the-ellis-island-medal-of-honor/2477358/Jim Mazzo, Global President of Ophthalmic Devices with Carl Zeiss Meditec, has been chosen to receive the Ellis Island Medal of Honor in 2020. The Ellis Island Honors Society honors the importance of immigration to America’s prosperity and celebrates the contributions immigrants and their
- Nicox’s End-of-Phase 2 Meeting With the FDA Sets Stage for NCX 470 Phase 3 Program in Glaucomahttps://modernod.com/news/nicoxs-end-of-phase-2-meeting-with-the-fda-sets-stage-for-ncx-470-phase-3-program-in-glaucoma/2477350/Nicox announced that it has successfully completed an end-of-phase 2 meeting with the FDA and agreed on the design for the NCX 470 phase 3 program, as well as nonclinical and CMC plans supporting submission of a new drug application (NDA) in the U.S. NCX 470, a novel second generation nitric oxid
- Scientists Use Revolutionary Gene-Editing Tool to Edit Inside a Patienthttps://modernod.com/news/in-a-1st-scientists-use-revolutionary-gene-editing-tool-to-edit-inside-a-patient/2477349/For the first time, scientists have used the gene-editing technique CRISPR to try to edit a gene while the DNA is still inside a person’s body, according to an NPR
- Nature Gene Therapy Publishes Preclinical Data of Ocugen’s OCU400 Genetic Modifier to Treat Retinitis Pigmentosahttps://modernod.com/news/nature-gene-therapy-publishes-preclinical-data-of-ocugens-ocu400-genetic-modifier-to-treat-retinitis-pigmentosa/2477345/Ocugen announced the publication in Nature Gene Therapy of preclinical data of nuclear hormone receptor gene NR2E3 as a genetic modifier and therapeutic agent to treat multiple retinal degenerative diseases. OCU400 (NR2E3-AAV) has received two orphan drug designatio
- Salus University and National Vision Partner to Educate Optometry Students on Remote Eye Exam Technologyhttps://modernod.com/news/salus-university-and-national-vision-partner-to-educate-optometry-students-on-remote-eye-exam-technology/2477343/Salus University has partnered with National Vision to advance optometric education via a pilot program focused on training students on conducting remote eye exams utilizing high-tech equipment and real-time secure HD video conferencing. The technology enables optometrists to see patients remotel
- EMA Grants Two Product Designations to Janssen’s RPGR Gene Therapy for X-Linked Retinitis Pigmentosahttps://modernod.com/news/ema-grants-two-product-designations-to-janssens-rpgr-gene-therapy-for-x-linked-retinitis-pigmentosa/2477338/The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Medicines Agency (EMA) has granted both PRIME (PRIority MEdicines) and Advanced Therapy Medicinal Product (ATMP) designations to the company’s adeno-associated virus (AAV)-RPGR gene t
- Orbis International Secures $500,000 Grant for Flying Eye Hospitalhttps://modernod.com/news/orbis-international-secures-500000-grant-for-flying-eye-hospital/2477337/The Conrad N. Hilton Foundation will invest $500,000 to support the sight-saving work Orbis International carries out on its Flying Eye Hospital, the world’s only fully accredited ophthalmic teaching hospital on board an MD-10 aircraft. The one-time gran
- Graybug Vision Presents Preclinical Results for Glaucoma Drug Candidate GB-401https://modernod.com/news/graybug-vision-presents-preclinical-results-for-glaucoma-drug-candidate-gb-401/2477332/Graybug Vision presented preclinical study results for GB-401, a novel injectable depot formulation of a proprietary beta-adrenergic antagonist prodrug, as a potential sustained-delivery treatment of up to 6 months for primary open angle glaucoma (POAG), at the American Glaucoma Society annual me